close and back to page

Latest News

Latest News

Abbott Tests Ace the Test of Time

In a need-for-speed medical world, Abbott's diagnostics rise up to the challenge, helping deliver better patient outcomes.

ABBOTT

Abbott is No. 10 on the DiversityInc Top 50 Companies List 


Suppose for a moment you're a doctor. Or a nurse. Or any healthcare professional.

In your world, you're seeing more patients than ever and more of them are older. New diseases are emerging and mutating. You're under more pressure to keep costs down. And time is of the essence – your patient would really just like to know what's wrong. Now. You'd like to know, too.

Feeling the pressure?

Today, diagnostic testing influences up to 70 percent of health care decisions worldwide. People expect and sometimes need fast, accurate test results so their doctors can assign a proper diagnosis and get their patients on the fastest route to recovery.

Abbott's all over that idea. With about 1.5 billion people estimated to reach 65 or older by 2050, and chronic diseases projected to account for between half and three-fourths of the disease burden by 2030, Abbott's diagnostics business will be innovating to help people live longer, healthier lives for many years to come.

Since 1972, Abbott has driven innovation across medical diagnostics, pioneering new technologies and solutions that transform the way patients and healthcare providers receive accurate and timely results for diseases such as cancers, infectious disease, cardiovascular and more. Today, it's an industry leader in the large $50 billion global diagnostics market.

About 4 billion tests are conducted each year using Abbott testing platforms; its platforms screen 60 percent of the world's blood supply and the business holds No. 1 positions in point-of-care testing (U.S.) and blood screening (U.S. and globally). In all, Abbott's diagnostics business achieved $4.8 billion in sales in 2016 and is known as a consistent driver of results for the company with mid-to-high single digit sales growth the past several years.

The secret lies in not just bringing a test to a customer – but solutions to their challenges. That means having the right menu of high quality tests, scalability for labs of all sizes, and the informatics tools that help labs operate more efficiently while elevating the role that diagnostics plays in helping patients.

Recently, Abbott began rolling out a family of diagnostic instruments designed to help simplify diagnostic testing while delivering results that drive better patient outcomes.

The name of the family, Alinity, is derived from a combination of "alignment," "innovation" and "unity." The harmonized family of next-generation diagnostic systems covers key areas of testing and positions Abbott to change the industry's testing paradigm and expedite patient care worldwide. It offers improved automation, throughput, space efficiency, speed of diagnosis and ease of use. These new platforms maximize the testing output within a smaller footprint – an important feature for labs that process tens of thousands of patient samples, but are often short on space.

All this, combined with the company's innovative informatics tools?

You might say it helps take the pressure off.

Abbott: Top Internship for Healthcare and Tech

Interns have spoken: Abbott is the top college internship program for healthcare and tech & engineering.

Originally Published by Abbott.

Abbott recognizes the need to develop its future leaders early, and has been named the top healthcare and tech & engineering internship program by Vault.

Read More Show Less

New Study Shows Abbott's Novel Diagnostic Test Could Help Rule Out Heart Attacks Earlier

Preliminary research indicates that a diagnostic test currently in development, that is done at the patient's side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack .

Originally Published by Abbott.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Read More Show Less

Abbott: Partnering for a Healthier Future

Abbott supports the First Ladies of Africa in the fight to end AIDS in children and keep mothers healthy.

Originally Published by Abbott.

In countries around the world, Abbott is working across its businesses and in partnerships with others to create healthier futures for families. One example: since 2014, Abbott's diagnostics business has supported the work of the Organization of African First Ladies Against HIV/AIDS (OAFLA – pictured above) to fight the AIDS epidemic in Africa, particularly among pregnant women and children – who are among the most vulnerable populations impacted by the disease.

At an OAFLA meeting on the sidelines of the UN General Assembly in New York City, Abbott and several other organizations are being recognized by OAFLA for longstanding partnership and support, including public-private partnerships that bring together technical, financial and other resources to focus on a global health challenge such as HIV/AIDS.

Read More Show Less

Abbott: DRG Stimulator, A Life Changing Technology for Chronic Pain.

The new technological DRG therapy may be the key to easing daily tasks for those with chronic pain.

Originally Published by Abbott.

Living with chronic pain affects not just your body but also your mind. It can make getting around and getting along equally difficult.

But with innovation in health technology comes hope. Abbott has developed a new device found to be more effective than traditional therapy at relieving chronic pain.

Read More Show Less

Abbott: Expediting Blood Testing With i-Stat

The portable, handheld i-STAT Alinity delivers quick blood test results anywhere you are.

Originally Published by Abbott.

Every day, countless blood samples are tested all around the world for one purpose: to help diagnose and treat medical conditions. From the couple eagerly awaiting the results of a pregnancy blood test to a worried cancer patient hoping for more answers, diagnostic blood tests give vital insight into what's happening underneath the skin.

Read More Show Less

Abbott: Freestyle Libre 14 Day, Now FDA Approved

Abbott's flash glucose monitor now FDA-approved for two weeks of use in U.S. between sensor changes.

Originally Published by Abbott.

The U.S. Food and Drug Administration has approved FreeStyle Libre 14 day— Abbott's revolutionary continuous glucose monitoring system. In the U.S., you can wear the sensor up to 14 days with high accuracy.

Read More Show Less

At Abbott, You Look Like An Engineer

Decades before #ILookLikeAnEngineer, Abbott paved the way for a non-profit dedicated to diversity in STEM.

Originally Published by Abbott.

#ILookLikeAnEngineer.

Remember this? A few years ago, a young software engineer was featured in a recruiting advertisement, only to be accused of not being an actual engineer. Frustrated with the assertion, Isis Wenger started a movement to break the stereotype of what an engineer should look like.

Read More Show Less

Abbott Receives FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves

MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair.

Originally Published by Abbott.

Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last ten years.

Read More Show Less